APA (7th ed.) Citation

A, C., TC, Y., A, V., F, R., T, T., G, S., . . . M, R. (2026). Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. European journal of cancer (Oxford, England : 1990), 240, 116750. https://doi.org/10.1016/j.ejca.2026.116750

Chicago Style (17th ed.) Citation

A, Casadei-Gardini, et al. "Early and Late Survival Dynamics of Immunotherapy Combinations in Advanced HCC: Anchored Indirect Comparison of Atezolizumab Plus Bevacizumab Versus Durvalumab + tremelimumab." European Journal of Cancer (Oxford, England : 1990) 240 (2026): 116750. https://doi.org/10.1016/j.ejca.2026.116750.

MLA (9th ed.) Citation

A, Casadei-Gardini, et al. "Early and Late Survival Dynamics of Immunotherapy Combinations in Advanced HCC: Anchored Indirect Comparison of Atezolizumab Plus Bevacizumab Versus Durvalumab + tremelimumab." European Journal of Cancer (Oxford, England : 1990), vol. 240, 2026, p. 116750, https://doi.org/10.1016/j.ejca.2026.116750.